TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dendritic Cell Vaccine in HIV-1 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed HIV infection~* CD4 \> 450 x 10 6 /L~* baseline VL \>10,000 c/ml before any HAART~* Part I, patients off HAART at least during 6 months~* Part II, Patients on HAART with PVL \< 200 copies/ml at least during 6 months~* Written informed consent .~Exclusion Criteria:~* Patients with failure to HAART~* Patients with B or C symptoms (CDC classification 1993).~* Age \< 18 years old.~* Pregnant or breastfeeding women~* Patients with baseline creatinin \> 2.5 mg/dl~* Patients with baseline GOT/GPT \> 250 UI/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pulsed dendritic cells untreated patients (Type: ACTIVE_COMPARATOR): Untreated patients receiving a dendritic cell based vaccine pulsed with autologous heat iactivated virus
- non pulsed dendritic cells untreated patients (Type: PLACEBO_COMPARATOR): None
- pulsed dendritic cell treated patient (Type: ACTIVE_COMPARATOR): treated patients will be immunized with a dendritic cell vaccine pulsed with heat inactivated autologous virus immediately before art interruption
- pulsed dendritic cell in treated patients (Type: ACTIVE_COMPARATOR): patients will be immunized with a dendritic cell vaccine pulsed with heat inactivted autologous virus immediately after interruption of art
- non pulsed dendritic cells (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18-75 years, inclusive~* Diagnosed with type 2 diabetes~* Stable dose of sulfonylurea alone or in combination with other anti-diabetic medications for 90 days~* Hemoglobin A1c value 7.5% to 9.5%, inclusive~* C peptide \> 0.5 ng/mL~* Prescribed ADA diet~Exclusion Criteria:~* History of type 1 diabetes or ketoacidosis~* History of pancreatitis~* Uncontrolled hypertension~* Allergy or toxic response to colesevelam or any of its components~* Serum LDL-C \< 60 mg/dL~* Serum TG \> 500 mg/dL~* Body mass index (BMI) \> 45 kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age 4 through 55 years~* Clinical history of allergy to peanuts or peanut-containing foods~* Serum immunoglobulin E (IgE) to peanut ≥0.35 kUA/L (kilos of allergen-specific units per liter, determined by UniCAP™\* within the past 12 months) and/or a skin prick test (SPT) to peanut ≥3 mm compared to control~* Experience dose-limiting symptoms at or before the 100 mg challenge dose of peanut protein (measured as 200 mg of peanut flour) on Screening DBPCFC conducted in accordance with PRACTALL\*\* guidelines~* Not be residing at the same address as another subject in this or any peanut OIT study~UniCAP™\*: a laboratory system for routine diagnostic testing of allergy and tool for basic studies on allergens and antibodies~PRACTALL\*\*: PRACTical issues in ALLergology Joint United States/European Union Initiative~Key Exclusion Criteria:~* History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension~* History of severe or life-threatening episode of anaphylaxis or anaphylactic shock within 60 days of Screening DBPCFC~* History of chronic disease (other than asthma, atopic dermatitis, or allergic rhinitis) that is, or is at significant risk of becoming, unstable or requiring a change in chronic therapeutic regimen~* History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD), symptoms of dysphagia or recurrent gastrointestinal symptoms of undiagnosed etiology~* History of severe asthma (NHLBI criteria steps 5 or 6), or mild to moderate asthma (2007 NHLBI criteria steps 1-4) that is uncontrolled or difficult to control~* History of steroid medication use~* History of a mast cell disorder, including mastocytosis, urticarial pigmentosa, and hereditary or idiopathic angioedema~* Developing dose-limiting symptoms in reaction to the placebo part of the Screening DBPCFC~* Having the same place of residence as another subject in the study

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- AR101 powder provided in capsules & sachets (Type: EXPERIMENTAL): Study product provided as peanut protein in pull-apart capsules or sachets
- Placebo powder provided in capsules & sachets (Type: PLACEBO_COMPARATOR): Placebo formulation in pull-apart capsules or sachets containing only inactive ingredients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: ECOLOGIC_OR_COMMUNITY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults aged ≥21yo.~* Asymptomatic 24h before the administration of booster dose.~* Has no active or previous RT-PCR lab-confirmed COVID-19 diagnosis.~* Completed three months to six months after the second dose of BBIBP-CorV.~* Have at least one Antibody test done before receiving the BBIBP-CorV booster dose OR can be done if the participant is yet to receive the BNT162b2 booster dose.~* Tested negative using Rapid Antigen Detection Test on the day of receiving the booster (positive results will confirm with RT-PCR).~* Study participants must have the ability to give informed consent.~Exclusion Criteria:~* Children aged \<21yo.~* Symptomatic within 24h before the administration of booster dose.~* Has active or previous RT-PCR lab-confirmed COVID-19 diagnosis.~* Did not complete three months to six months after the second dose of BBIBP-CorV.~* Does not have at least one Antibody test done before receiving the BBIBP-CorV booster dose~* Tested positive using Rapid Antigen Detection Test on the day of receiving the booster (positive results will be confirmed with PCR).~* Patients unable to give informed consent.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Homologous booster (Type: None): Two doses of BBIBP-CorV, followed by BBIBP-CorV
- Heterologous booster (Type: None): Two doses of BBIBP-CorV, followed by BNT162b2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.~* Subject had a clinical diagnosis of psoriasis for at least 6 months, had moderate to severe plaque psoriasis.~* Subject was able and willing to self-administer sc injections or had available qualified person(s) to administer sc injections~Exclusion Criteria:~* Subject had previously received anti-TNF therapy.~* Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy~* Subject cannot avoid excessive sun exposure~* Subject is taking or requires oral or injectable corticosteroids~* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study~* Female subject who is pregnant or breast-feeding or considering becoming pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Self-management of Blood Pressure Medication for Hypertensive Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible participants are those with who have a clinical diagnosis of hypertension~* Who are not currently at their in-clinic goal blood pressure (\>130 or \> 90 at minimum)~* Are able to provide independent informed consent and expected to be in the area for at least 12 months~Exclusion Criteria:~* Criteria for exclusion will include: active prescriptions for \> 2 antihypertensive agents~* Known allergies to 2 or more antihypertensive agents~* Currently not primarily in charge of his/her own medication administration, e.g.:~  * those living in institutions or with dementia or other limitations making self medication care not possible~* Life expectancy of less than 12 months~* Blood pressure at screening visit \> 180 mm Hg systolic or \> 110 diastolic, or \< 120 systolic~* Screening cognitive function (Montreal Assessment of Cognitive Function, MoCA) 48 score less than 25~* eGFR \< 25 ml/min /1.73m2 or end-stage renal disease (ESRD)~* Inability to use a standard home blood pressure cuff~* Known secondary cause of hypertension that causes concern regarding safety of the protocol, in the opinion of the site investigator~* Cardiovascular event or hospitalization for unstable angina within last 3 months~* Symptomatic heart failure within the past 6 months or left ventricular ejection fraction \< 35%~* Pregnancy or planned pregnancy, or of child-bearing age not using birth control~* Current participation in another clinical trial~* Or major factors judged to be likely to significantly limit comprehension of or adherence to interventions including:~  * dementia~ * psychiatric disease~ * substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- self-management (Type: EXPERIMENTAL): Participants will be taught to monitor blood pressure and make limited adjustments to their medications
- usual care (Type: NO_INTERVENTION): Participants will be enrolled in the study and undergo a baseline, 6 month, and 1 year visit but their hypertension care will be per usual care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-infected HIV infection will be confirmed by two different rapid tests (as per South African national Department of Health guidelines) and an HIV viral load test.~2. CD4 count \< 100/μL One CD4 count taken within 3 months prior to enrolment less than 100/μL will qualify, even if other CD4 counts are greater than 100/μL~3. ART-naïve Patients who report having been treated with triple drug or dual drug ART previously will be excluded. Single dose nevirapine or short term AZT monotherapy for PMTCT is not an exclusion.~4. Confirmed diagnosis of TB (smear, culture, Xpert MTB/RIF test or compatible histology) or strong clinical and radiological evidence of TB with symptomatic response to TB treatment~5. On TB treatment for less than 30 days prior to study entry.~6. Eligible for ART and patient consents to starting ART within 30 days of starting TB treatment.~7. Written informed consent for trial~Exclusion Criteria:~1. Kaposi's sarcoma (KS) A thorough examination for KS lesions will be performed and any suspicious lesion will be biopsied. Any history of treatment for KS will also be an exclusion.~2. Pregnant All female participants of child-bearing potential will have a pregnancy test performed prior to enrollment and will be counseled to use to two reliable methods of contraception for the duration of the trial.~3. \<18 years old~4. TB meningitis or tuberculoma at TB diagnosis~5. Clinical syndrome of pericardial TB at TB diagnosis (a pericardial effusion noted on ultrasound scan alone is not an exclusion criterion)~6. Rifampicin-resistant TB diagnosed by Xpert MTB/RIF test or a drug susceptibility test performed on a culture isolate.~7. On corticosteroids for another indication or on any other immunosuppressive medication within the past 7 days.~8. Uncontrolled diabetes mellitus~9. The following abnormal laboratory values:~   Alanine aminotransferase \> 200 IU/l Absolute neutrophil count \< 500/mm3~10. Not on standard intensive phase TB treatment (Rifampicin, isoniazid, pyrazinamide and ethambutol)~11. Poor clinical response to TB treatment prior to ART as judged by the clinical investigators.~12. Hepatitis B surface antigen positive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prednisone (Type: EXPERIMENTAL): Prednisone oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Motivational Interviewing to Enhance Adherence of Patients With Psychogenic Non-epileptic Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The study population will be screened from all patients diagnosed with PNES in Brigham and Women's Hospital by capture of a definitive event on video EEG without EEG correlate.~* Patients with a mixed diagnosis of both PNES and epileptic seizures will be included.~Exclusion Criteria:~* Pediatric patients (under age 18) are not evaluated by EEG in our hospital and will therefore be excluded~* Estimated IQ\<70~* Active substance use disorder~* Pregnancy or active medical issues anticipated to preclude participation in weekly psychotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- control (Type: ACTIVE_COMPARATOR): Group will receive standard treatment for psychogenic non-epileptic seizures. They will undergo an initial clinic visit with a neuropsychiatrist and neurologists. They will not undergo any subsequent motivational interview. Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference.
- MI (Type: EXPERIMENTAL): Group will receive an initial clinic visit with a neuropsychiatrist and neurologists, identical to the initial clinic visit for the control group. In addition they will receive 1 session of motivational interviewing immediately following the initial clinic visit. These patients will be questioned using standardized motivational interviewing techniques by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.~Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference (identical treatment in control and MI arms).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Milk-Borne Transmission of HIV-1C in Botswana

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mothers must be no more than 34 weeks pregnant, intending to carry to term, intending to stay in area for at least 7 months, and consenting to HIV-1 testing and participation; HIV-1 infected by ELISA confirmed by Western blot; etc.

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- maternal nevirapine (Type: ACTIVE_COMPARATOR): None
- maternal placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pirfenidone and Advanced Liver Fibrosis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with chronic liver disease whose fibrosis continued to progress despite abstaining from alcohol (ALD), achieving sustained virologic response (VHC), or otherwise maintaining stable disease (NAFLD, AIH)..~2. Advanced liver fibrosis defined as fibrosis grade 3 or grade 4 according to METAVIR scale based in two non-invasive liver fibrosis evaluation methods (FibroScan and Fibrotest).~3. Stable liver disease.~Exclusion Criteria:~1. Patients with mild fibrosis (F1-F2)~2. Under medication with colchicine, silymarin, non-steroidal anti-inflammatory drugs, and any hepatotoxic drug.~3. Decompensation based on a history of hepatic encephalopathy, esophageal variceal bleeding, or ascites in the previous 6 months~4. HIV, Hepatitis B virus (HBV) or any active infectious processes not of a self-limited nature.~5. Concomitant or prior history of malignancy other than curatively-treated skin cancer or surgically-cured in situ carcinoma of the cervix.~6. Hemoglobinopathy or any disease associated with hemolysis.~7. History of significant cardiac or pulmonary disease that could be exacerbated by anemia.~8. Liver masses detected by baseline scanner or Alpha-fetoprotein \>100 ng/L.~9. Pregnancy.~10. Alcohol or intravenous drug abuse within the previous year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Antifibrotic plus standard of care treatment (Type: EXPERIMENTAL): Prolonged release pirfenidone formulation in combination with standard of care treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevalence of Sleep Apnea in Patients Presenting for Hip or Knee Replacement Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years old and older~* Planned total hip or total knee arthroplasty~* Referral to the internal medicine preoperative evaluation clinic~Exclusion Criteria:~• None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Berlin (Type: None): Patients diagnosed with obstructive sleep apnea by polysomnography after being screened with the Berlin questionnaire.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Participants with metastatic RCC who have failed 2 or 3 prior systemic regimens, one of which includes a VEGFR TKI other than sorafenib or tivozanib.~* Histologically or cytologically confirmed RCC with a clear cell component (participants with pure papillary cell tumor or other non-clear cell histologies, including collecting duct, medullary, chromophobe, and unclassified RCC are excluded).~* Measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) criteria Version 1.1.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~* Life expectancy ≥ 3 months.~Exclusion Criteria:~* Prior treatment with sorafenib or tivozanib.~* More than 3 prior regimens for metastatic RCC.~* Known central nervous system (CNS) metastases other than stable, treated brain metastases. Participants with previously treated brain metastasis will be allowed if the brain metastasis has been stable by neuroimaging without steroid treatment for at least 3 months following prior treatment (radiotherapy or surgery).~* Significant hematologic, gastrointestinal, thromboembolic, vascular, bleeding, or coagulation disorders.~* Significant serum chemistry abnormalities~* Significant cardiovascular disease, including: Active clinically symptomatic left ventricular failure, uncontrolled hypertension, myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of study drug, history of serious ventricular arrhythmia, cardiac arrhythmias requiring anti-arrhythmic medications.~* Inadequate recovery from any prior surgical procedure or major surgical procedure within 4 weeks prior to administration of first dose of study drug.~* Currently active second primary malignancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tivozanib hydrochloride (Type: EXPERIMENTAL): Participants randomized to this arm will receive the study drug, tivozanib hydrochloride.
- Sorafenib (Type: ACTIVE_COMPARATOR): Participants randomized to this arm will receive the comparator drug, sorafenib.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete